Dry Spray Hemostatic System Using Synthetic Platelets

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for controlling hemorrhaging in traumatic injuries, such as those in the central nervous system, are inadequate as they often result in uncontrolled bleeding due to the limitations of platelet substitutes, external hemostatic agents, and the challenges of administering recombinant factor VIIa, which is expensive and requires refrigeration, necessitating a new approach for immediate and effective hemostasis.

Innovation Solution

Development of dry spray compositions comprising co-block polymers coupled with water-soluble polymers and peptides, specifically RGD sequences, that act as synthetic platelets for targeted hemostasis, providing quick and even distribution at the wound site, stability at room temperature, and specific aggregation properties to prevent non-specific thrombosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic platelets are administered to control hemorrhaging, then bleeding can be halted, but platelets have short shelf life and can cause graft versus host disease, alloimmunization, and transfusion-associated lung injuries

Engineering Contradiction:

Improvehemostasis effectivenessVSAvoidtransfusion complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates synthetic platelets that replicate the hemostatic functions of natural platelets without using actual biological platelets. These synthetic platelets are composed of fibrinogen-coated microcapsules based on albumin, copying the essential clotting function while avoiding all transfusion-related complications such as graft versus host disease, alloimmunization, and transfusion-associated lung injuries.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The synthetic platelets use albumin as a base material, which is inexpensive, readily available, and has a long shelf life compared to natural platelets. The microcapsule structure allows these synthetic platelets to be stored without refrigeration and administered when needed, eliminating the short shelf life problem of natural platelets while maintaining effective hemostasis.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If recombinant factor VIIa is administered intravenously to augment hemostasis, then bleeding control can be achieved, but it requires refrigeration, is expensive, and has mixed results making it challenging to administer in the field

Engineering Contradiction:

Improvehemostasis effectivenessVSAvoidfield administration feasibility

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent replaces the complex biochemical cascade required for natural hemostasis with a simplified mechanical approach: fibrinogen-coated microcapsules that directly bind to exposed collagen at the injury site and recruit platelets through physical adsorption and specific binding, bypassing the need for recombinant factor VIIa and its associated refrigeration and cost issues.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Productivity

If spray on hemostatic systems are developed for quick and even distribution, then application to difficult-to-contact areas is enabled, but the system needs to be non-toxic, stable at room temperature, and avoid non-specific thrombosis

Engineering Contradiction:

Improveapplication speed and coverageVSAvoidnon-specific thrombosis and toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The synthetic platelets are designed with localized functionality: fibrinogen coating on the microcapsule surface provides specific binding affinity for exposed collagen at the injury site, while the albumin core provides structural stability. This localized functional design ensures that hemostatic activity is concentrated exactly where needed (at the collagen-exposed wound bed) rather than systemically throughout the bloodstream, preventing non-specific thrombosis.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The synthetic platelets combine multiple materials with complementary properties: albumin provides a biocompatible, stable core structure; fibrinogen coating provides specific binding to collagen and platelet recruitment; and the microcapsule structure provides controlled delivery. This composite material design achieves both effective localized hemostasis and systemic safety.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dry spray compositions significantly reduce bleeding time in trauma models by acting as synthetic platelets, offering a stable, effective, and easily applicable solution for hemostasis, even in hard-to-reach areas, with the potential to improve tissue preservation and functional outcomes.

Implementation Method 1

nanoparticles that act essentially as synthetic platelets and are stable at room temperature

Methodology Applied

Scientific EffectRGD sequence binding: Adsorption

Implementation Method 2

The ultimate step, clot formation, is the conversion of fibrinogen, a large, soluble plasma protein produced by the liver and normally present in the plasma, into fibrin, an insoluble, threadlike molecule

Methodology Applied

Scientific EffectCoagulation: Coagulation